Harrow completes transfer of NDAs for several ophthalmic products
Click Here to Manage Email Alerts
Eye care pharmaceutical company Harrow announced the completed transfer of new drug applications for Flarex, Natacyn, Tobradex ST, Verkazia and Zerviate, all of which were acquired in July and will now be launched under the company name.
“With the completion of the NDA transfer process for the branded ophthalmic portfolio that we recently acquired, our marketing and sales teams are hard at work implementing commercial strategies aimed at increasing brand awareness and sales for these products,” Mark L Baum, CEO of Harrow, said in a company press release.
Harrow provided the following product details in the release:
- Flarex (0.1% fluorometholone acetate ophthalmic suspension) is a corticosteroid for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the eye.
- Natacyn (5% natamycin ophthalmic suspension) is a sterile antifungal for treatment of fungal blepharitis, conjunctivitis and keratitis.
- Tobradex ST (tobramycin/dexamethasone ophthalmic suspension) is a combination therapy for steroid-responsive inflammatory ocular conditions.
- Verkazia (0.1% cyclosporine ophthalmic emulsion) is a calcineurin inhibitor immunosuppressant for treating vernal keratoconjunctivitis in children and adults.
- Zerviate (0.24% cetirizine ophthalmic solution) is a histamine-1 receptor agonist for ocular itching in patients with allergic conjunctivitis.
“These products and others we acquired this year support a growing awareness among U.S. eye care professionals that Harrow is exclusively focused on and committed to serving U.S. eye care professionals with a full range of high-quality, accessible and affordable products they need to care for their patients,” Baum said in the release.
Read more about
Click Here to Manage Email Alerts